Analysts expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post earnings of ($0.19) per share for the current quarter, according to Zacks. Five analysts have provided estimates for BioDelivery Sciences International’s earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.16). BioDelivery Sciences International reported earnings of ($0.27) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 29.6%. The business is scheduled to issue its next earnings report on Wednesday, August 8th.
On average, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.54). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.61) to ($0.20). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. The business had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.77 million. BioDelivery Sciences International had a negative net margin of 122.75% and a negative return on equity of 388.58%.
BDSI has been the topic of several recent analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a report on Thursday, March 15th. HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, March 19th. Roth Capital set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, May 11th. Finally, ValuEngine upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Buy” and an average target price of $4.07.
In other news, Director Mark A. Sirgo sold 100,000 shares of the business’s stock in a transaction dated Tuesday, April 10th. The shares were sold at an average price of $2.06, for a total transaction of $206,000.00. Following the completion of the sale, the director now directly owns 2,585,966 shares of the company’s stock, valued at $5,327,089.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the business’s stock in a transaction dated Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the sale, the chief financial officer now directly owns 97,731 shares of the company’s stock, valued at $204,257.79. The disclosure for this sale can be found here. Insiders own 9.00% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its position in shares of BioDelivery Sciences International by 88.9% during the fourth quarter. Wells Fargo & Company MN now owns 67,081 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 31,575 shares in the last quarter. GSA Capital Partners LLP grew its position in BioDelivery Sciences International by 12.7% in the 1st quarter. GSA Capital Partners LLP now owns 460,567 shares of the specialty pharmaceutical company’s stock worth $1,036,000 after purchasing an additional 51,900 shares in the last quarter. Two Sigma Investments LP bought a new stake in BioDelivery Sciences International in the 4th quarter worth about $166,000. BlueCrest Capital Management Ltd bought a new stake in BioDelivery Sciences International in the 4th quarter worth about $201,000. Finally, Goldman Sachs Group Inc. bought a new stake in BioDelivery Sciences International in the 4th quarter worth about $223,000. 46.13% of the stock is owned by institutional investors.
BioDelivery Sciences International opened at $2.95 on Wednesday, Marketbeat.com reports. The company has a debt-to-equity ratio of 35.82, a quick ratio of 1.13 and a current ratio of 1.40. BioDelivery Sciences International has a 12-month low of $1.70 and a 12-month high of $3.60.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.